Stanley B. Kahler has over 30 years of experience in analytical chemistry and clinical research coordination. He received his Bachelor of Arts in Chemistry from Union College in 1989. Since 2009, he has worked as a Clinical Research Coordinator at Clinical Trials Management Resources, LLC. Prior to that, he held analytical chemistry roles at several pharmaceutical companies focusing on analytical development and services. He has coordinated multiple phase 3 clinical trials for conditions like osteoarthritis and gout.
Eficacia de poractan vs beractan en sra metanalisis
Stan Kahler CV 2016
1. CURRICULUM VITAE
STANLEY B. KAHLER, B.A.
Clinical Trials Management Resources, LLC
3585 Deer Valley Dr, Castle Rock, CO 80104
Phone 720-270-2309 email: sbkahler66@gmail.com
Education
Bachelor of Arts Union College
Chemistry Lincoln, NE
1989
Experience
Clinical Trials Management Resources, LLC 2009-present
Clinical Research Coordinator
Cedarburg Hauser Pharmaceuticals 2011-2012
Denver, CO
Analytical Chemist
Anlaytical Services
Array Biopharma, Inc. 2006-2009
Longmont, CO
Research Associate
Analytical Research and Development
Mayne Pharma 2005-2006
(formerly Napro Biotherapeutics, now Hospira)
Boulder, CO
Analytical Chemist
Technical Services Group
Tapestry Pharmaceuticals 2002-2005
(formerly Napro Biotherapeutics)
Boulder, CO
Chemist
Analytical Development/Chemistry Development
Napro Biotherapeutics 2000-2002
Boulder, CO
Chemist
Analytical Development/Chemistry Development
Rosemont Pharmaceuticals 1993-2000
(now Upsher Smith)
Analytical Chemist
Harris Laboratories 1990-1992
Lincoln, NE
Analytical Chemist
2. Stanley B. Kahler, B.A.
Page 2 of 3
Union College, Lincoln, NE 1985-1989
Full time student
Investigative Trials
Clinical Research Coordinator. A Phase 3, Multi-center, Randomized, Double-Blind, Controlled
Study of the Long-Term Analgesic Efficacy and Safety of Tanezumab Alone or in
Combination with Non-Steroidal Anti-inflammatory Drugs (NSAIDS ) versus NSAIDS
Alone in Patients with Osteoarthritis of the Knee or Hip. Pfizer Inc. Jan 2009-May 2009.
Clinical Research Coordinator. A 26 Week, Double-Blind, Randomized, Placebo-Controlled Study
of the Efficacy and Safety of Single Intra-Articular Injection 1.2% Sodium Hyaluronate for
Treatment of Painful Osteoarthritis of the Knee, with Optional 26-Week Open-Label Safety
Extension. Ferring International Pharmascience Center, U.S., Inc. August 2009-April 2011.
Clinical Research Coordinator. Long-term Allopurinol Safety Study Evaluating Outcomes in Gout
Patients (LASSO). Ardea Biosciences, Inc. November 2011-May 2013.
Clinical Research Coordinator. A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-
Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and
Allopurinol Compared to Allopurinol Alone in Subjects with Gout who have had an
Inadequate Hypouricemic Response to Standard of Care Allopurinol (CLEAR 1). Ardea
Biosciences, Inc. March 2012-September 2014.
Clinical Research Coordinator. A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-
Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to
Placebo in Subjects with Gout who have had an Intolerance or Contraindication to a
Xanthine Oxidase Inhibitor (LIGHT). Ardea Biosciences, Inc. March 2012- November 2013
Clinical Research Coordinator. A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-
Controlled Combination Study to Evaluate the Efficacy and Safety of Lesinurad and
Febuxostat Compared to Febuxostat Alone at Lowering Serum Uric Acid and Resolving
Tophi in Subjects with Tophaceous Gout (CRYSTAL). Ardea Biosciences, Inc. March
2012-July 2014.
Clinical Research Coordinator. A Long-Term Open-Label Study for Subjects Completing
a Phase 3 Efficacy and Safety Study of Lesinurad Monotherapy in Subjects with Gout.
LIGHT Extension Study. Ardea Biosciences, Inc. November 2012-July 2014.
Clinical Research Coordinator. A Long-Term Extension Study of Lesinurad in Combination with
Allopurinol for Subjects Completing an Efficacy and Safety Study of Lesinurad and
Allopurinol. CLEAR Extension Study. Ardea Biosciences, Inc. August 2013-present.
Clinical Research Coordinator. A Long-Term Extension Study of Lesinurad in Combination with
Febuxostat for Subjects with Gout Completing an Efficacy and Safety Study of Lesinurad
and Febuxostat. CRYSTAL Extension Study. Ardea Biosciences, Inc. May 2013-present.
3. Stanley B. Kahler, B.A.
Page 3 of 3
Clinical Research Coordinator. A Multi-Center, Randomized, Double-Blind, Phosphate Buffered
Saline-Controlled Study to Evaluate Effectiveness and Safety of a Single Intra-Articular
Injection of Gel-One® for the Treatment of Osteoarthritis of the Knee with Open-Label
Safety Extension. August 2013 - April 2016
Clinical Research Coordinator. A Study to Determine the Presence and Volume of Monosodium
Urate Crystals as Assessed by Dual-Energy Computed Tomography in Gout Patients
Treated with Allopurinol. May 2015 – March 2016